US EditionPublished • loading... • Updated
The Changing Economics of Allergy Care: 2021-2025 Data Report
A ModuleMD analysis shows biologics now make up 25%-35% of allergy practice revenue as core service reimbursements fail to keep pace with inflation.
- From GRAND BLANC, Mich., the report states ModuleMD released a reimbursement analysis on Jan. 14, 2026, showing rapid shifts in allergy care economics.
- Between rising operating costs and flat payments, allergy practices face a structural shift as reimbursements for core allergy services lag by 12–15% versus healthcare inflation, ModuleMD finds.
- Biologics and infusion services now represent 25–35% of collections in practices that administer them, while CPT codes and payer contracts reimburse nearly 2x depending on geography.
- Practices facing margin squeeze risk elevated financial harm, but top-performing practices using analytics, automation and AI-enabled workflows show about ~2% higher revenue per provider.
- ModuleMD urges Allergy & Immunology practices to prioritize rapid adaptation, as 2021–2025 claims dataset shows economics shifting faster than many realize, recommending smarter revenue mix, payer diversification, automation and real-time intelligence.
Insights by Ground AI
14 Articles
14 Articles
The Norfolk Daily News+13 Reposted by 13 other sources
The Changing Economics of Allergy Care: 2021-2025 Data Report
GRAND BLANC, Mich., Jan. 14, 2026 /PRNewswire/ -- Allergy reimbursements are falling behind inflation. Learn how top-performing practices are using biologics, AI, and payer diversification to increase revenue by 22%.
Coverage Details
Total News Sources14
Leaning Left1Leaning Right0Center5Last UpdatedBias Distribution83% Center
Bias Distribution
- 83% of the sources are Center
83% Center
L 17%
C 83%
Factuality
To view factuality data please Upgrade to Premium
